These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9532644)

  • 1. [Efficacy of moxonidine, an imidazoline receptor agonist, in patients with essential hypertension].
    Baliakina EV; Patrusheva IF; Rynskova EE; Iurenev AP
    Ter Arkh; 1998; 70(1):15-9. PubMed ID: 9532644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of the imidazoline receptor agonist moxonidine on hemodynamics, coronary circulation, metabolic ischemia markers and the neurohumoral system in patients with essential hypertension. Effects of moxonidine on coronary circulation].
    Mitrovic V; Hamel M; Miric M; Thormann J; Hamm C
    Z Kardiol; 2001 Dec; 90(12):953-63. PubMed ID: 11826837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the effectiveness of moxonidine and prestarium in postmenopausal women with mild and moderate arterial hypertension].
    Bakhshaliev AB; Sabzalieva GM
    Klin Med (Mosk); 2006; 84(4):41-4. PubMed ID: 16755855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ACE-dependent and sympathetic components of blood pressure regulation in patients with essential hypertension].
    Aparina TV; Gomazkov OA; Dilakian EA; Britov AN
    Vopr Med Khim; 2001; 47(4):411-8. PubMed ID: 11693029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxonidine: a review.
    Morris ST; Reid JL
    J Hum Hypertens; 1997 Oct; 11(10):629-35. PubMed ID: 9400904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives.
    Wenzel RR; Spieker L; Qui S; Shaw S; Lüscher TF; Noll G
    Hypertension; 1998 Dec; 32(6):1022-7. PubMed ID: 9856967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus].
    Lazebnik LB; Malichenko SB; Serebrov AN
    Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279
    [No Abstract]   [Full Text] [Related]  

  • 16. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
    Palkhiwala SA; Yu A; Frishman WH
    Heart Dis; 2000; 2(1):83-92. PubMed ID: 11728244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imidazole receptor agonists--a new advance in the treatment of hypertension?].
    Spinar J; Vítovec J
    Vnitr Lek; 2000 Feb; 46(2):122-5. PubMed ID: 11048538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of hypertension patients with Estulic].
    Baliakina EV; Anuchin VV; Patrusheva IF; Iurenev AP
    Ter Arkh; 1996; 68(12):57-60. PubMed ID: 9054043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
    Papp JG; Ollivier JP
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():v-vi. PubMed ID: 7533220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.